首页> 外文OA文献 >A Study on the Potential of Active Constituent from Senna spectabilis in Treating Leishmania major Infection
【2h】

A Study on the Potential of Active Constituent from Senna spectabilis in Treating Leishmania major Infection

机译:番泻叶有效成分治疗利什曼原虫感染的潜力研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Leishmaniasis affects millions of people each year. It consists of a group of tropical infections that are effecting human populations in mainly low-income countries. Visceral Leishmaniasis (VL) and Cutaneous Leishmaniasis (CL) are the main forms of Leishmaniasis which cause mortality, chronic disability and poverty. Leishmanasis is among three of most neglected diseases in the world, together with Human African Trypanosomiasis (HAT) and Chagas’ disease. These diseases are termed as neglected diseases because they are receiving very limited press attention as well as research funding as compared to HIV/AIDS, tuberculosis and malaria. In 2003, Drugs for Neglected Diseases Initiative (DNDi) which is a non-profit drug R&D agency focusing on developing new treatments for neglected diseases was established
机译:利什曼病每年影响数百万人。它由一组热带感染组成,这些感染主要影响低收入国家的人口。内脏利什曼病(VL)和皮肤利什曼病(CL)是导致死亡,慢性残疾和贫穷的主要形式的利什曼病。利什曼病与人类非洲锥虫病(HAT)和南美锥虫病(Chagas's disease)一起,是世界上三种最常被忽视的疾病。这些疾病被称为被忽视的疾病,因为与艾滋病毒/艾滋病,结核病和疟疾相比,它们受到的新闻报道和研究资金很少。 2003年,非营利药物研发机构(DNDi)成立了专注于开发被忽视疾病新疗法的非营利药物开发机构(DNDi)

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号